Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis.
- Author:
Jin Hwa LEE
1
;
Jung Hyun CHANG
Author Information
1. Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. hs1017@mm.ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Tuberculosis;
Receptor Antagonist Interleukin-1;
Interleukin-8
- MeSH:
Blood Sedimentation;
Body Mass Index;
Body Weight;
C-Reactive Protein;
Drug Therapy*;
Ferritins;
Granuloma;
Hematocrit;
Humans;
Interleukin 1 Receptor Antagonist Protein;
Interleukin-1*;
Interleukin-8*;
Interleukins;
Leukocytes;
Macrophages;
Macrophages, Alveolar;
Mycobacterium;
Mycobacterium tuberculosis;
Plasma*;
Platelet Count;
T-Lymphocytes;
Tuberculosis;
Tuberculosis, Pulmonary*
- From:Korean Journal of Medicine
2002;62(5):513-521
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The human immune response to Mycobacterium tuberculosis is mediated by macrophage and T-lymphocyte. The alveolar macrophage phagocyting mycobacterium produced interleukin (IL)-1 as an inflammatory mediator and IL-8 as a cytokine for leukocyte recruitment and granuloma formation. Interleukin-1 receptor antagonist (IL-1ra) is an internal antagonist of IL-1. METHODS: Plasma levels of IL-1ra and IL-8 and other serologic markers were measured in 18 patients with active tuberculosis before treatment and after 2 months and 6 months of treatment. RESULTS: During treatment with antituberculous medication, patients showed significant changes of hemoglobin, hematocrit, white blood cell (WBC), platelet counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferritin and plasma IL-1ra. After 2 months of treatment, ESR and CRP were significantly diminished as compared with those before treatment. After 6 months of treatment, hemoglobin was increased and WBC, platelet counts, ESR, CRP and ferritin decreased significantly as compared with those before treatment. At each point of observation the group of delayed therapeutic response showed lower body weight, hemoglobin and hematocrit and higher WBC, platelet counts, ESR, IL-8 and IL-1ra than those of early responsive group. During the time course of treatment, significant differences were observed in body weight, body mass index, hemoglobin, hematocrit, WBC, platelet counts, ESR, CRP and ferritin for each group of early and delayed response. CONCLUSION: Plasma concentrations of IL-1ra and IL-8 might indirectly reflect their different patterns of secretion and functions with different peaks during the course of treatment and they seemed not so sensitive as other inflammatory markers to evaluate the disease activity during antituberculous treatment. However, IL-1ra can be considered a marker of disease activity and response of treatment.
